Can we safely omit anthracyclins out of neoadjuvant chemotherapy for selected patients with early TNBCs? And which patients? Dr. Hatem A. Azim Jr (Adjunct professor, Monterrey Institute of Oncology) explained to us his opinion on our live discussion, and give us a summary of supporting evidence.
.png)
.png)